Tuberculosis in an inflammatory bowel disease cohort from South Africa

dc.contributor.authorDeetlefs, E
dc.contributor.authorEpstein, D
dc.contributor.authorWatermeyer, G A
dc.contributor.authorSeggie, R M
dc.contributor.authorThomson, S R
dc.date.accessioned2021-10-08T07:18:01Z
dc.date.available2021-10-08T07:18:01Z
dc.date.issued2012
dc.description.abstractBackground. Potent immunosuppressive therapy is standard treatment for inflammatory bowel disease (IBD) but carries a risk of reactivating latent tuberculosis (TB). No data exist on the burden of TB in South African patients with IBD. Objective. To evaluate the burden of TB in IBD patients attending a large tertiary IBD clinic. Methods. A retrospective analysis was performed on data pertaining to patients attending the Groote Schuur Hospital IBD clinic. Data were extracted from an existing IBD database, patient notes, the National Health Laboratory Services database and chest X-ray analysis. Results. Of 614 patients, 72 (11.7%) were diagnosed with TB; 40 (55.6%) developed TB prior to the diagnosis of IBD. On regression analysis, coloured IBD patients were at increased risk for TB development (p=0.004, odds ratio (OR) 3.57, 95% confidence interval (CI) 1.49 - 8.56), as were patients with extensive Crohn’s disease (CD) compared with those with less extensive disease (p=0.001,OR 2.84, 95% CI 1.27 - 6.33). No other risk factors, including the use of immunosuppressive agents, were identified for the development of TB. Conclusions. Of over 600 patients, 12% had TB either before or after IBD diagnosis. The high rate of previous TB and positive association with ethnicity probably reflects the high burden of TB in a socio-economically disadvantaged community. We recommend that IBD patients should be screened actively and monitored for TB when immunosuppressive medications are used.
dc.identifier.apacitationDeetlefs, E., Epstein, D., Watermeyer, G. A., Seggie, R. M., & Thomson, S. R. (2012). Tuberculosis in an inflammatory bowel disease cohort from South Africa. <i>South African Medical Journal</i>, 102(10), 802 - 177. http://hdl.handle.net/11427/34884en_ZA
dc.identifier.chicagocitationDeetlefs, E, D Epstein, G A Watermeyer, R M Seggie, and S R Thomson "Tuberculosis in an inflammatory bowel disease cohort from South Africa." <i>South African Medical Journal</i> 102, 10. (2012): 802 - 177. http://hdl.handle.net/11427/34884en_ZA
dc.identifier.citationDeetlefs, E., Epstein, D., Watermeyer, G.A., Seggie, R.M. & Thomson, S.R. 2012. Tuberculosis in an inflammatory bowel disease cohort from South Africa. <i>South African Medical Journal.</i> 102(10):802 - 177. http://hdl.handle.net/11427/34884en_ZA
dc.identifier.issn0038-2469
dc.identifier.ris TY - Journal Article AU - Deetlefs, E AU - Epstein, D AU - Watermeyer, G A AU - Seggie, R M AU - Thomson, S R AB - Background. Potent immunosuppressive therapy is standard treatment for inflammatory bowel disease (IBD) but carries a risk of reactivating latent tuberculosis (TB). No data exist on the burden of TB in South African patients with IBD. Objective. To evaluate the burden of TB in IBD patients attending a large tertiary IBD clinic. Methods. A retrospective analysis was performed on data pertaining to patients attending the Groote Schuur Hospital IBD clinic. Data were extracted from an existing IBD database, patient notes, the National Health Laboratory Services database and chest X-ray analysis. Results. Of 614 patients, 72 (11.7%) were diagnosed with TB; 40 (55.6%) developed TB prior to the diagnosis of IBD. On regression analysis, coloured IBD patients were at increased risk for TB development (p=0.004, odds ratio (OR) 3.57, 95% confidence interval (CI) 1.49 - 8.56), as were patients with extensive Crohn’s disease (CD) compared with those with less extensive disease (p=0.001,OR 2.84, 95% CI 1.27 - 6.33). No other risk factors, including the use of immunosuppressive agents, were identified for the development of TB. Conclusions. Of over 600 patients, 12% had TB either before or after IBD diagnosis. The high rate of previous TB and positive association with ethnicity probably reflects the high burden of TB in a socio-economically disadvantaged community. We recommend that IBD patients should be screened actively and monitored for TB when immunosuppressive medications are used. DA - 2012 DB - OpenUCT DP - University of Cape Town IS - 10 J1 - South African Medical Journal LK - https://open.uct.ac.za PY - 2012 SM - 0038-2469 T1 - Tuberculosis in an inflammatory bowel disease cohort from South Africa TI - Tuberculosis in an inflammatory bowel disease cohort from South Africa UR - http://hdl.handle.net/11427/34884 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34884
dc.identifier.vancouvercitationDeetlefs E, Epstein D, Watermeyer GA, Seggie RM, Thomson SR. Tuberculosis in an inflammatory bowel disease cohort from South Africa. South African Medical Journal. 2012;102(10):802 - 177. http://hdl.handle.net/11427/34884.en_ZA
dc.language.isoeng
dc.publisher.departmentDivision of Radiology
dc.publisher.facultyFaculty of Health Sciences
dc.sourceSouth African Medical Journal
dc.source.journalissue10
dc.source.journalvolume102
dc.source.pagination802 - 177
dc.source.urihttps://dx.doi.org/10.7196/SAMJ.5609
dc.subject.otherTuberculosis
dc.subject.otherInflammatory Bowel Disease
dc.subject.otherCrohn's disease
dc.subject.otherUlcerative colitis
dc.titleTuberculosis in an inflammatory bowel disease cohort from South Africa
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
DeetlefsE_Tuberculosis_in_2012.pdf
Size:
88.3 KB
Format:
Adobe Portable Document Format
Description:
Collections